The CXCL5/CXCR2 axis is sufficient to promote breast cancer colonization during bone metastasis

Ricardo Romero-Moreno, Kimberly J. Curtis, Thomas R. Coughlin, Maria Cristina Miranda-Vergara, Shourik Dutta, Aishwarya Natarajan, Beth A. Facchine, Kristen M. Jackson, Lukas Nystrom, Jun Li, William Kaliney, Glen L. Niebur and Laurie E. Littlepage ()
Additional contact information
Ricardo Romero-Moreno: Harper Cancer Research Institute
Kimberly J. Curtis: Harper Cancer Research Institute
Thomas R. Coughlin: Harper Cancer Research Institute
Maria Cristina Miranda-Vergara: Harper Cancer Research Institute
Shourik Dutta: Harper Cancer Research Institute
Aishwarya Natarajan: Harper Cancer Research Institute
Beth A. Facchine: Harper Cancer Research Institute
Kristen M. Jackson: Harper Cancer Research Institute
Lukas Nystrom: Loyola University Medical Center, Stritch School of Medicine
Jun Li: Harper Cancer Research Institute
William Kaliney: Harper Cancer Research Institute
Glen L. Niebur: Harper Cancer Research Institute
Laurie E. Littlepage: Harper Cancer Research Institute

Nature Communications, 2019, vol. 10, issue 1, 1-14

Abstract: Abstract Bone is one of the most common sites for metastasis across cancers. Cancer cells that travel through the vasculature and invade new tissues can remain in a non-proliferative dormant state for years before colonizing the metastatic site. Switching from dormancy to colonization is the rate-limiting step of bone metastasis. Here we develop an ex vivo co-culture method to grow cancer cells in mouse bones to assess cancer cell proliferation using healthy or cancer-primed bones. Profiling soluble factors from conditioned media identifies the chemokine CXCL5 as a candidate to induce metastatic colonization. Additional studies using CXCL5 recombinant protein suggest that CXCL5 is sufficient to promote breast cancer cell proliferation and colonization in bone, while inhibition of its receptor CXCR2 with an antagonist blocks proliferation of metastatic cancer cells. This study suggests that CXCL5 and CXCR2 inhibitors may have efficacy in treating metastatic bone tumors dependent on the CXCL5/CXCR2 axis.

Date: 2019
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-019-12108-6 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-12108-6

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-019-12108-6

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().